

Pharmacist-Led Transitions of Care: Improving Outcomes for Extended Thromboprophylaxis in High-Risk Medically Ill Patients

Selected References

1. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. *Scott Med J*. 1981;26:115-117.
2. Samama MM, Cohen AT, Darmon JY, et al. Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med*. 1999;341:793-800.
3. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004;110:874-879.
4. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ*. 2006;332:325-329.
5. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients antithrombotic therapy and prevention of thrombosis. *Chest*. 2012;141:e195S–e226S.
6. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for the management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv*. 2018;2:3198-3225.
7. Heit JA, O’Fallon WH, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*. 2002;162:1245-1248.
8. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. *Arch Intern Med*. 2007;167:1471-1475.
9. Amin A, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. *J Hosp Med*. 2012;7:231-238.
10. Hull RD, Schellong SM, Tapson VF, et al, for the EXCLAIM study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Ann Intern Med*. 2010;153:8-18.
11. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, for the ADOPT investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med*. 2011;365:2167-2177.
12. Cohen AT, Spiro TE, Büller HR, et al, for the MAGELLAN investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med*. 2013;368:513-523.
13. Cohen AT, Harrington RA, Goldhaber SZ, et al, for the APEX investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. *N Engl J Med*. 2016;375:534-544.
14. Spyropoulos AC, Lipardi C, Xu J, et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. *Clin Appl Thromb Hemost*. 2019;25:1-9.
15. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. *N Engl J Med*. 2018;379:1118-1127.
16. Cohen AT, Huang W, Harrington RA, et al. Prevalence of major medical illnesses associated with venous thromboembolism risk in US hospitals. *Res Pract Thromb Haemost*. 2017;1:177-178.
17. Miao B, Chalupadi B, Clark B, et al. Proportion of US hospitalized medically ill patients who may qualify for extended prophylaxis. *Clin Appl Thromb Hemost*. 2019;25:1-6.
18. VTE prophylaxis for the medically ill patient (updated 2020). Anticoagulation Forum. Accessed April 15, 2021. https://acforumexcellence.org/Resource-Center/resource_files/-2020-03-31-071701.pdf.

SF 309094-P

19. Barkoudah E, Piazza G, Hecht TEH, et al. Extended venous thromboembolism prophylaxis in medically ill patients: an NATF anticoagulation action initiative. *Am J Med.* 2020;133(Suppl 1):1-27.